Silicon Laboratories, Inc. SLAB
221.24
(0.14)
(0.06%)
as of 25 Sep
- Market cap
- $7.4B
- P/E
- 0.0×
Follow SLAB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.48 | 8.36 | 5.45 | 5.80 | |
P/FCF ratio |
0.00 | 389.69 | 65.01 | 70.35 | |
P/Operating CF |
(500.10) | 1,390.61 | 512.17 | 125.45 | |
P/B ratio |
6.63 | 6.25 | 3.91 | 4.02 | |
Price to Tangible BV |
10.37 | 9.78 | 6.15 | 6.44 | |
EV/Sales |
8.69 | 8.53 | 5.62 | 5.98 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
224.66 | 133.24 | 46.05 | 45.56 | |
EV/FCF |
(1,368.71) | 397.40 | 67.00 | 72.57 | |
Quick Ratio |
3.84 | 3.89 | 3.53 | 3.48 | |
Current Ratio |
5.41 | 5.11 | 4.69 | 4.49 | |
Net Debt/EBITDA |
176.71 | 50.21 | (88.90) | 110.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.69 | 0.66 | 0.63 | 0.59 | |
Operating CF/Net income |
1.37 | (0.31) | (3.11) | (3.45) | |
Capex/Depreciation |
(1.46) | (1.18) | (1.21) | (0.76) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
41.64% | 41.50% | 43.00% | 42.57% | |
Selling, General and Administrative Expense of Revenue |
24.68% | 25.99% | 22.00% | 21.20% | |
Intangible Assets out of Total Assets |
0.32 | 0.31 | 0.31 | 0.32 | |
Share Based Compensation of Revenue |
11.24% | 9.86% | 9.93% | 9.73% | |
Graham Net Nets |
0.07 | 0.07 | 0.12 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.54%) | (0.74%) | (1.52%) | (2.01%) | |
Free Cash Flow Yield |
(0.07%) | 0.26% | 1.54% | 1.42% | |
Revenue per Share |
6.87 | 6.48 | 6.36 | 6.27 | |
Operating CF per Share |
(0.44) | 0.15 | 0.26 | 1.05 | |
Capex per Share |
(0.37) | (0.30) | (0.30) | (0.19) | |
Free Cash Flow per Share |
(0.81) | (0.15) | (0.05) | 0.85 | |
Cash per Share |
11.96 | 13.31 | 13.56 | 13.37 | |
Shareholders Equity per Share |
32.97 | 33.33 | 33.45 | 32.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
32.97 | 33.33 | 33.45 | 32.61 | |
Free Cash Flow |
(26.83) | (4.90) | (1.63) | 27.93 | |
Working Capital |
547.08 | 543.84 | 530.23 | 507.25 | |
Capital Expenditures |
(12.32) | (9.84) | (9.98) | (6.39) | |
Net Current Asset Value |
512.97 | 508.39 | 499.12 | 470.21 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.03 | |
Net Profit Margin |
(4.64%) | (7.45%) | (1.29%) | (4.82%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
68.15 | 64.59 | 59.50 | 58.09 | |
Average Payables |
55.28 | 55.10 | 46.58 | 50.15 | |
Average Inventory |
102.11 | 93.31 | 100.60 | 110.84 | |
Average Assets |
1,237.06 | 1,247.98 | 1,246.00 | 1,251.15 | |
Average Common Equity |
1,077.94 | 1,083.48 | 1,087.22 | 1,076.05 |
Columns are period end dates